JP2021503962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503962A5 JP2021503962A5 JP2020547260A JP2020547260A JP2021503962A5 JP 2021503962 A5 JP2021503962 A5 JP 2021503962A5 JP 2020547260 A JP2020547260 A JP 2020547260A JP 2020547260 A JP2020547260 A JP 2020547260A JP 2021503962 A5 JP2021503962 A5 JP 2021503962A5
- Authority
- JP
- Japan
- Prior art keywords
- norovirus
- protein
- plant
- vlp
- gii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001263478 Norovirus Species 0.000 claims 28
- 101710132601 Capsid protein Proteins 0.000 claims 26
- 101710197658 Capsid protein VP1 Proteins 0.000 claims 26
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims 26
- 101710108545 Viral protein 1 Proteins 0.000 claims 26
- 150000001413 amino acids Chemical group 0.000 claims 8
- 229940024606 amino acid Drugs 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 101710081079 Minor spike protein H Proteins 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- 235000014304 histidine Nutrition 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 229960002885 histidine Drugs 0.000 claims 4
- 235000018977 lysine Nutrition 0.000 claims 4
- 229960003646 lysine Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 235000008521 threonine Nutrition 0.000 claims 4
- 229960002898 threonine Drugs 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- 229960005261 aspartic acid Drugs 0.000 claims 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 3
- 235000004554 glutamine Nutrition 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 229960002743 glutamine Drugs 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 235000014705 isoleucine Nutrition 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 235000005772 leucine Nutrition 0.000 claims 3
- 229960003136 leucine Drugs 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 235000014393 valine Nutrition 0.000 claims 3
- 229960004295 valine Drugs 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 229960003767 alanine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 229960002989 glutamic acid Drugs 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000006109 methionine Nutrition 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 229960004452 methionine Drugs 0.000 claims 2
- 229960001153 serine Drugs 0.000 claims 2
- 235000004400 serine Nutrition 0.000 claims 2
- 208000006339 Caliciviridae Infections Diseases 0.000 claims 1
- 101000846901 Drosophila melanogaster Fat-body protein 1 Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- -1 aspartin Chemical compound 0.000 claims 1
- 230000004186 co-expression Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024084260A JP2024109835A (ja) | 2017-11-30 | 2024-05-23 | 改変ノロウイルスｖｐ１タンパク質及び改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593006P | 2017-11-30 | 2017-11-30 | |
| US62/593,006 | 2017-11-30 | ||
| US201862712744P | 2018-07-31 | 2018-07-31 | |
| US62/712,744 | 2018-07-31 | ||
| PCT/CA2018/051530 WO2019104439A1 (en) | 2017-11-30 | 2018-11-30 | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024084260A Division JP2024109835A (ja) | 2017-11-30 | 2024-05-23 | 改変ノロウイルスｖｐ１タンパク質及び改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503962A JP2021503962A (ja) | 2021-02-15 |
| JP2021503962A5 true JP2021503962A5 (enExample) | 2021-12-23 |
| JP7579143B2 JP7579143B2 (ja) | 2024-11-07 |
Family
ID=66663733
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547260A Active JP7579143B2 (ja) | 2017-11-30 | 2018-11-30 | 改変ノロウイルスｖｐ１タンパク質及び改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ |
| JP2024084260A Abandoned JP2024109835A (ja) | 2017-11-30 | 2024-05-23 | 改変ノロウイルスｖｐ１タンパク質及び改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024084260A Abandoned JP2024109835A (ja) | 2017-11-30 | 2024-05-23 | 改変ノロウイルスｖｐ１タンパク質及び改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11602558B2 (enExample) |
| EP (1) | EP3717648A4 (enExample) |
| JP (2) | JP7579143B2 (enExample) |
| KR (1) | KR102878449B1 (enExample) |
| CN (1) | CN111727255A (enExample) |
| AU (1) | AU2018375695B2 (enExample) |
| BR (1) | BR112020010799A2 (enExample) |
| CA (1) | CA3083857A1 (enExample) |
| IL (1) | IL274736A (enExample) |
| MX (1) | MX2020005530A (enExample) |
| PH (1) | PH12020550732A1 (enExample) |
| RU (1) | RU2020116307A (enExample) |
| SG (1) | SG11202004668WA (enExample) |
| WO (1) | WO2019104439A1 (enExample) |
| ZA (2) | ZA202003831B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7420339B2 (ja) * | 2019-10-11 | 2024-01-23 | 学校法人北里研究所 | 変異ノロウイルス粒子とその生産方法 |
| WO2022081870A1 (en) * | 2020-10-14 | 2022-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Stabilized norovirus virus-like particles as vaccine immunogens |
| CN113481328B (zh) * | 2021-07-23 | 2023-10-27 | 中国科学院微生物研究所 | 用于检测临床样本中gi.5型诺如病毒的试剂盒及专用引物 |
| CN118450902A (zh) * | 2021-10-27 | 2024-08-06 | 宾夕法尼亚大学理事会 | 诺如病毒疫苗及使用方法 |
| CN118252924A (zh) * | 2022-12-27 | 2024-06-28 | 远大赛威信生命科学(南京)有限公司 | 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途 |
| WO2025077799A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Products Co., Ltd. | Method of preparing norovirus vaccine without adjuvant |
| WO2025076792A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Product Co., Ltd. | Methods of preparing norovirus vaccine with low amounts of adjuvant |
| CN118126202B (zh) * | 2024-05-07 | 2024-07-30 | 上海瑞宙生物科技有限公司 | 一种诺如病毒类病毒颗粒及其应用 |
| CN118773218B (zh) * | 2024-08-22 | 2025-09-30 | 中国医学科学院医学生物学研究所 | 一种诺如病毒gii.17型病毒样颗粒及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| DK2324113T3 (en) * | 2008-08-08 | 2018-04-16 | Takeda Vaccines Inc | VIRUS-LIKE PARTICLES INCLUDING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR INCREASED CRYSTAL REACTIVITY |
| DK2480560T3 (en) | 2009-09-22 | 2018-04-16 | Medicago Inc | PROCEDURE FOR THE PREPARATION OF PLANT DERIVATIVE PROTEINS |
| CN103154242B (zh) | 2010-07-06 | 2015-09-30 | 诺华股份有限公司 | 诺如病毒衍生的免疫原性组合物和方法 |
| EP2956169B1 (en) | 2013-02-12 | 2018-04-11 | THE UNITED STATES OF AMERICA, represented by the S | Monoclonal antibodies that neutralize norovirus |
| US9975923B2 (en) | 2013-03-15 | 2018-05-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| US10000556B2 (en) | 2013-05-09 | 2018-06-19 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use |
| JP5963811B2 (ja) | 2014-07-18 | 2016-08-03 | オリンパス株式会社 | 治療用超音波振動子 |
| EP3037386A1 (en) | 2014-12-23 | 2016-06-29 | Casale SA | A plant and a process for ammonia production with cryogenic purification, and a related method of revamping |
| CA2988761A1 (en) | 2015-06-12 | 2016-12-15 | Vaxart, Inc. | Formulations for small intestinal delivery of rsv and norovirus antigens |
| EP4631970A2 (en) | 2016-05-04 | 2025-10-15 | CureVac SE | Nucleic acid molecules and uses thereof |
| CA3056812C (en) * | 2017-03-23 | 2022-11-29 | Medicago Inc. | Norovirus fusion proteins and vlps comprising norovirus fusion proteins |
-
2018
- 2018-11-30 AU AU2018375695A patent/AU2018375695B2/en active Active
- 2018-11-30 JP JP2020547260A patent/JP7579143B2/ja active Active
- 2018-11-30 EP EP18883648.0A patent/EP3717648A4/en active Pending
- 2018-11-30 PH PH1/2020/550732A patent/PH12020550732A1/en unknown
- 2018-11-30 WO PCT/CA2018/051530 patent/WO2019104439A1/en not_active Ceased
- 2018-11-30 CA CA3083857A patent/CA3083857A1/en active Pending
- 2018-11-30 CN CN201880077956.8A patent/CN111727255A/zh active Pending
- 2018-11-30 BR BR112020010799-9A patent/BR112020010799A2/pt not_active Application Discontinuation
- 2018-11-30 SG SG11202004668WA patent/SG11202004668WA/en unknown
- 2018-11-30 US US16/768,524 patent/US11602558B2/en active Active
- 2018-11-30 KR KR1020207018576A patent/KR102878449B1/ko active Active
- 2018-11-30 RU RU2020116307A patent/RU2020116307A/ru unknown
- 2018-11-30 MX MX2020005530A patent/MX2020005530A/es unknown
-
2020
- 2020-05-18 IL IL274736A patent/IL274736A/en unknown
- 2020-06-24 ZA ZA2020/03831A patent/ZA202003831B/en unknown
-
2023
- 2023-02-07 US US18/165,804 patent/US12076388B2/en active Active
- 2023-06-23 ZA ZA2023/06500A patent/ZA202306500B/en unknown
-
2024
- 2024-05-23 JP JP2024084260A patent/JP2024109835A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503962A5 (enExample) | ||
| RU2020116307A (ru) | Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса | |
| CN1142271C (zh) | 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗 | |
| WO2023186170A1 (zh) | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 | |
| JP2010227101A5 (enExample) | ||
| CN107847580A (zh) | 针对rsv的疫苗 | |
| EP3393507A1 (en) | Zika virus purification | |
| RU2014116371A (ru) | Повышение выхода вирусоподобных частиц в растениях | |
| JP2014519817A5 (enExample) | ||
| CN108456663B (zh) | 一种1型牛病毒性腹泻病毒样颗粒及其制备与应用 | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| JP2019500320A5 (enExample) | ||
| RU2015113826A (ru) | Выделение вируса, родственного парвовирусу-2 собак, от енота | |
| WO2019163781A1 (ja) | エンテロウイルスワクチン | |
| JP2014527526A5 (enExample) | ||
| CN120202019A (zh) | 重组lsdv载体口蹄疫抗原构建体 | |
| JP2012517239A5 (enExample) | ||
| JP2021524273A5 (enExample) | ||
| RU2018112060A (ru) | Слитый белок | |
| CN107635579A (zh) | 非天然发生的猪生殖和呼吸综合征病毒(prrsv)和使用方法 | |
| CN104151402B (zh) | 病毒性心肌炎环肽疫苗及其制备方法 | |
| EP4232082A1 (en) | Baculovirus expression vector | |
| KR102733185B1 (ko) | 중동호흡기증후군 코로나바이러스 및 이의 용도 | |
| CN1137896C (zh) | 新型口蹄疫疫苗及其制备方法 | |
| RU2020143519A (ru) | Мутанты гемагглютинина вируса гриппа |